Citation
McAndrews, Kathleen M., et al. "Heterogeneous Antibodies Against SARS-CoV-2 Spike Receptor Binding Domain and Nucleocapsid With Implications for COVID-19 Immunity." JCI Insight, vol. 5, no. 18, 2020.
McAndrews KM, Dowlatshahi DP, Dai J, et al. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight. 2020;5(18).
McAndrews, K. M., Dowlatshahi, D. P., Dai, J., Becker, L. M., Hensel, J., Snowden, L. M., Leveille, J. M., Brunner, M. R., Holden, K. W., Hopkins, N. S., Harris, A. M., Kumpati, J., Whitt, M. A., Lee, J. J., Ostrosky-Zeichner, L. L., Papanna, R., LeBleu, V. S., Allison, J. P., & Kalluri, R. (2020). Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight, 5(18). https://doi.org/10.1172/jci.insight.142386
McAndrews KM, et al. Heterogeneous Antibodies Against SARS-CoV-2 Spike Receptor Binding Domain and Nucleocapsid With Implications for COVID-19 Immunity. JCI Insight. 2020 09 17;5(18) PubMed PMID: 32796155.
TY - JOUR
T1 - Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
AU - McAndrews,Kathleen M,
AU - Dowlatshahi,Dara P,
AU - Dai,Jianli,
AU - Becker,Lisa M,
AU - Hensel,Janine,
AU - Snowden,Laura M,
AU - Leveille,Jennifer M,
AU - Brunner,Michael R,
AU - Holden,Kylie W,
AU - Hopkins,Nikolas S,
AU - Harris,Alexandria M,
AU - Kumpati,Jerusha,
AU - Whitt,Michael A,
AU - Lee,J Jack,
AU - Ostrosky-Zeichner,Luis L,
AU - Papanna,Ramesha,
AU - LeBleu,Valerie S,
AU - Allison,James P,
AU - Kalluri,Raghu,
Y1 - 2020/09/17/
PY - 2020/07/17/received
PY - 2020/08/13/accepted
PY - 2020/8/17/pubmed
PY - 2020/9/30/medline
PY - 2020/8/16/entrez
KW - Adaptive immunity
KW - COVID-19
KW - Immunology
JF - JCI insight
JO - JCI Insight
VL - 5
IS - 18
N2 - Evaluation of potential immunity against the novel severe acute respiratory syndrome (SARS) coronavirus that emerged in 2019 (SARS-CoV-2) is essential for health, as well as social and economic recovery. Generation of antibody response to SARS-CoV-2 (seroconversion) may inform on acquired immunity from prior exposure, and antibodies against the SARS-CoV-2 spike protein receptor binding domain (S-RBD) are speculated to neutralize virus infection. Some serology assays rely solely on SARS-CoV-2 nucleocapsid protein (N-protein) as the antibody detection antigen; however, whether such immune responses correlate with S-RBD response and COVID-19 immunity remains unknown. Here, we generated a quantitative serological ELISA using recombinant S-RBD and N-protein for the detection of circulating antibodies in 138 serial serum samples from 30 reverse transcription PCR-confirmed, SARS-CoV-2-hospitalized patients, as well as 464 healthy and non-COVID-19 serum samples that were collected between June 2017 and June 2020. Quantitative detection of IgG antibodies against the 2 different viral proteins showed a moderate correlation. Antibodies against N-protein were detected at a rate of 3.6% in healthy and non-COVID-19 sera collected during the pandemic in 2020, whereas 1.9% of these sera were positive for S-RBD. Approximately 86% of individuals positive for S-RBD-binding antibodies exhibited neutralizing capacity, but only 74% of N-protein-positive individuals exhibited neutralizing capacity. Collectively, our studies show that detection of N-protein-binding antibodies does not always correlate with presence of S-RBD-neutralizing antibodies and caution against the extensive use of N-protein-based serology testing for determination of potential COVID-19 immunity.
SN - 2379-3708
UR - https://www.unboundmedicine.com/medline/citation/32796155/Heterogeneous_antibodies_against_SARS_CoV_2_spike_receptor_binding_domain_and_nucleocapsid_with_implications_for_COVID_19_immunity_
L2 - https://doi.org/10.1172/jci.insight.142386
DB - PRIME
DP - Unbound Medicine
ER -